MedTrace Logo

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

NCT02006888 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 394

Last updated 2018-04-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.

Conditions

Interventions

DRUG

IBI-10090

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • ICON Bioscience Inc

    lead INDUSTRY

Principal Investigators

  • howard franklin, md · ICON Bioscience Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02006888 on ClinicalTrials.gov